Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Part of paid clinical trials in New York, New York.

Sponsor
Remedy Plan, Inc.
Study ID
NCT07107126
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RPT1G — DRUG
    RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.

Study Details

The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

Key Dates

Start date
Feb 13, 2026
Status verified
Mar 2026
Primary completion
Dec 1, 2028
Completion
Dec 1, 2028

Study Design

Enrollment
24 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Starting Dose of RPT1G
  • Experimental: Cohort 2
    2nd ascending dose of RPT1G
  • Experimental: Cohort 3
    3rd ascending dose of RPT1G
  • Experimental: Cohort 4
    4th ascending dose of RPT1G

Primary Outcome Measure

Incidence and nature of dose-limiting toxicity(ies) (DLTs) [ Time Frame: 3 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in New York, NY

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Memorial Sloan Kettering Cancer Center· New York, NYMD Anderson Cancer Center· Houston, TX

Related Studies